查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1411542

癌症微生物組定序市場：按產品、技術、應用和最終用戶分類 - 2024-2030 年全球預測

Cancer Microbiome Sequencing Market by Product (Kits & Assays, Service, Software), Technology (Next-Generation Sequencing, Polymerase Chain Reaction), Application, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年癌症微生物定序市場規模為17.4億美元，預計2024年將達到18.4億美元，2030年將達到25.9億美元，複合年成長率為5.79%。

癌症微生物組定序的全球市場

主要市場統計
基準年[2023] 17.4億美元
預測年份 [2024] 18.4億美元
預測年份 [2030] 25.9億美元
複合年成長率（%） 5.79%
癌症微生物組定序市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估癌症微生物組定序市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出資訊的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可對癌症微生物組定序市場供應商的現況進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更資訊的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-癌症微生物組定序市場的市場規模和預測是多少？

2-在癌症微生物組定序市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3-癌症微生物組定序市場的技術趨勢和法律規範是什麼？

4-癌症微生物組定序市場主要廠商的市場佔有率是多少？

5- 進入癌症微生物組定序市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球癌症病例數不斷增加
      • 政府促進癌症預防、診斷和護理的舉措
      • 研究活動的數量不斷增加，人們對腸道微生物群重要性的認知也不斷提高
    • 抑制因素
      • 使用定序服務的成本較高，且缺乏熟練的人力資源。
    • 機會
      • 下一代定序的進展
      • 利用人工智慧、機器學習和生物資訊學實現癌症檢測
    • 任務
      • 與資料分析相關的技術限制和問題
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章癌症微生物組定序市場：依產品

  • 套件和檢測
  • 服務
  • 軟體

第7章癌症微生物組定序市場：依技術分類

  • 下一代定序
  • 聚合酶鍊式反應

第8章癌症微生物組定序市場：依應用分類

  • 診斷
  • 轉化研究

第 9 章癌症微生物組定序市場：依最終用戶分類

  • 學術研究所
  • 醫院和診斷實驗室
  • 製藥和生物技術公司

第10章美洲癌症微生物組定序市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太癌症微生物組定序市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的癌症微生物組定序市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析

第14章競爭產品組合

  • 主要公司簡介
    • Abbott Laboratories
    • Agilent Technologies, Inc.
    • AstraZeneca PLC
    • Athos Therapeutics Inc.
    • Bio-Rad Laboratories, Inc.
    • Bristol-Myers Squibb
    • CosmosID
    • Creative Biolabs
    • Evelo Biosciences
    • EzBiome
    • F. Hoffmann-La Roche AG
    • Ferring Pharmaceuticals
    • Illumina, Inc.
    • LC Sciences
    • Merck KGaA
    • Metagen Therapeutics
    • MV BioTherapeutics SA
    • Norgen Biotek Corp.
    • Novogene Co, Ltd.
    • Qiagen NV
    • Thermo Fisher Scientific Inc.
    • Vedanta Biosciences.
    • Viome Life Sciences, Inc.
  • 主要產品系列

第15章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-5C6F41F5AFAB

[182 Pages Report] The Cancer Microbiome Sequencing Market size was estimated at USD 1.74 billion in 2023 and expected to reach USD 1.84 billion in 2024, at a CAGR 5.79% to reach USD 2.59 billion by 2030.

Global Cancer Microbiome Sequencing Market

KEY MARKET STATISTICS
Base Year [2023] USD 1.74 billion
Estimated Year [2024] USD 1.84 billion
Forecast Year [2030] USD 2.59 billion
CAGR (%) 5.79%
Cancer Microbiome Sequencing Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer Microbiome Sequencing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer Microbiome Sequencing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer Microbiome Sequencing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., AstraZeneca PLC, Athos Therapeutics Inc., Bio-Rad Laboratories, Inc., Bristol-Myers Squibb, CosmosID, Creative Biolabs, Evelo Biosciences, EzBiome, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals, Illumina, Inc., LC Sciences, Merck KGaA, Metagen Therapeutics, MV BioTherapeutics SA, Norgen Biotek Corp., Novogene Co, Ltd., Qiagen NV, Thermo Fisher Scientific Inc., Vedanta Biosciences., and Viome Life Sciences, Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Microbiome Sequencing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Kits & Assays
    • Service
    • Software
  • Technology
    • Next-Generation Sequencing
    • Polymerase Chain Reaction
  • Application
    • Diagnostics
    • Translational Research
  • End User
    • Academic & Research Institutes
    • Hospitals & Diagnostic Laboratories
    • Pharmaceutical & Biotechnology Companies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cancer Microbiome Sequencing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer Microbiome Sequencing Market?

3. What are the technology trends and regulatory frameworks in the Cancer Microbiome Sequencing Market?

4. What is the market share of the leading vendors in the Cancer Microbiome Sequencing Market?

5. Which modes and strategic moves are suitable for entering the Cancer Microbiome Sequencing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cancer Microbiome Sequencing Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising number of cancer cases across the world
      • 5.1.1.2. Government initiatives to promote cancer prevention, diagnosis, and care
      • 5.1.1.3. Growing number of research activities and increasing awareness about the significance of gut microbiome
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of availing sequencing services and lack of skilled personnel
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in next-generation sequencing
      • 5.1.3.2. Utilization of AI, ML, and bioinformatics to enable cancer detection
    • 5.1.4. Challenges
      • 5.1.4.1. Technical limitations and difficulties associated with data analysis
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Cancer Microbiome Sequencing Market, by Product

  • 6.1. Introduction
  • 6.2. Kits & Assays
  • 6.3. Service
  • 6.4. Software

7. Cancer Microbiome Sequencing Market, by Technology

  • 7.1. Introduction
  • 7.2. Next-Generation Sequencing
  • 7.3. Polymerase Chain Reaction

8. Cancer Microbiome Sequencing Market, by Application

  • 8.1. Introduction
  • 8.2. Diagnostics
  • 8.3. Translational Research

9. Cancer Microbiome Sequencing Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Hospitals & Diagnostic Laboratories
  • 9.4. Pharmaceutical & Biotechnology Companies

10. Americas Cancer Microbiome Sequencing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cancer Microbiome Sequencing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cancer Microbiome Sequencing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. Abbott Laboratories
    • 14.1.2. Agilent Technologies, Inc.
    • 14.1.3. AstraZeneca PLC
    • 14.1.4. Athos Therapeutics Inc.
    • 14.1.5. Bio-Rad Laboratories, Inc.
    • 14.1.6. Bristol-Myers Squibb
    • 14.1.7. CosmosID
    • 14.1.8. Creative Biolabs
    • 14.1.9. Evelo Biosciences
    • 14.1.10. EzBiome
    • 14.1.11. F. Hoffmann-La Roche AG
    • 14.1.12. Ferring Pharmaceuticals
    • 14.1.13. Illumina, Inc.
    • 14.1.14. LC Sciences
    • 14.1.15. Merck KGaA
    • 14.1.16. Metagen Therapeutics
    • 14.1.17. MV BioTherapeutics SA
    • 14.1.18. Norgen Biotek Corp.
    • 14.1.19. Novogene Co, Ltd.
    • 14.1.20. Qiagen NV
    • 14.1.21. Thermo Fisher Scientific Inc.
    • 14.1.22. Vedanta Biosciences.
    • 14.1.23. Viome Life Sciences, Inc.
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. CANCER MICROBIOME SEQUENCING MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER MICROBIOME SEQUENCING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. CANCER MICROBIOME SEQUENCING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CANCER MICROBIOME SEQUENCING MARKET DYNAMICS
  • FIGURE 7. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 10. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 14. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. CANCER MICROBIOME SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. CANCER MICROBIOME SEQUENCING MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. CANCER MICROBIOME SEQUENCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. CANCER MICROBIOME SEQUENCING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SERVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 10. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 13. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TRANSLATIONAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 16. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. JAPAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. MALAYSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH KOREA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. TAIWAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. THAILAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. VIETNAM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 103. DENMARK CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. EGYPT CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. FINLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. FRANCE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. GERMANY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. ISRAEL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. ITALY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. NETHERLANDS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. NIGERIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. NORWAY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. POLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. QATAR CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. RUSSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. SAUDI ARABIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. SPAIN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. SWEDEN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWITZERLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. TURKEY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED ARAB EMIRATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. CANCER MICROBIOME SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 188. CANCER MICROBIOME SEQUENCING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 189. CANCER MICROBIOME SEQUENCING MARKET LICENSE & PRICING